「de」の検索結果
167件：106～110件目を表示
-
Supplement business | Business Activities | About Senju | SENJU Pharmaceutical
e health of all people. Senju Pharmaceutical, as a pioneer of ophthalmic drugs, has long engaged in developing prescription and OTC drugs to contribute to the health of all people. As our next mission...
https://www.senju.co.jp/english/about/business/ec.html -
Mytear HARD LENS WETTING SOLUTION | OTC Products, etc. | Products | SENJU Pharmaceutical
Designated quasi-drugs Mytear® HARD LENS WETTING SOLUTION Lubricates lenses, allows smooth insertion CHARACTERISTICS Viscous liquid forms a thin layer on the surface of hard or rigid gas permeable len...
https://www.senju.co.jp/english/products/wettingsolution.html -
学会发表 | 研究与开发 | 千寿制药株式会社
PV1拮抗薬モツギバトレプのドライアイ患者を対象とした第Ⅲ相比較試験 堀 裕一、和田智之、尾松和則 See more 海外 ARVO 2026 開催日：2026年5月３日～2026年5月7日 開催地：Denver, Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatr...
http://www.senju.co.jp/chinese/rd/society/ -
Mytear EYETECT | OTC Products, etc. | Products | SENJU Pharmaceutical
® EYETECT® To treat teary eyes due to eye strain, fatigue, etc. CHARACTERISTICS Mytear EYETECT includes the anti-inflammatory ingredient, pranoprofen [swich OTC Drug], and is effective for “teary eye”...
https://www.senju.co.jp/english/products/eyetect.html -
学会発表実績 | 研究開発活動 | 千寿製薬株式会社
規TRPV1拮抗薬モツギバトレプのドライアイ患者を対象とした第Ⅲ相比較試験 堀 裕一、和田智之、尾松和則 もっと見る 海外 ARVO 2026 開催日：2026年5月３日～2026年5月7日 開催地：Denver, Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatr...
https://www.senju.co.jp/rd/society/